HR-5668 : Still Just a Bill

Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020

This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.

Action Timeline

Action DateTypeTextSource
2020-11-18IntroReferralReceived in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Senate
2020-11-17FloorMotion to reconsider laid on the table Agreed to without objection.House floor actions
2020-11-17FloorOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)House floor actions
2020-11-17FloorDEBATE - The House proceeded with forty minutes of debate on H.R. 5668.House floor actions
2020-11-17FloorConsidered under suspension of the rules. (consideration: CR H5805-5807)House floor actions
2020-11-17FloorMr. Pallone moved to suspend the rules and pass the bill, as amended.House floor actions
2020-11-16CalendarsPlaced on the Union Calendar, Calendar No. 471.House floor actions
2020-11-16CommitteeReported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.House floor actions
2020-07-15CommitteeOrdered to be Reported (Amended) by Voice Vote.House committee actions
2020-07-15CommitteeCommittee Consideration and Mark-up Session Held.House committee actions
2020-03-11CommitteeSubcommittee Consideration and Mark-up Session Held.House committee actions
2020-03-11CommitteeOrdered to be Reported (Amended) by Voice Vote.House committee actions
2020-01-25CommitteeReferred to the Subcommittee on Health.House committee actions
2020-01-24IntroReferralReferred to the House Committee on Energy and Commerce.House floor actions
2020-01-24IntroReferralIntroduced in HouseLibrary of Congress

Policy Area :

Health
See Subjects
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • Prescription drugs

Related Bills

See Related Bills